Clinical characteristics of cryopyrin ‐associated periodic syndrome and long‐term real‐world efficacy and tolerability of canakinumab in Japan: results of a nationwide survey

ConclusionsThis study provides one of the largest epidemiologic datasets for CAPS. While early initiation of anti-IL-1 treatment with canakinumab is beneficial for improving disease prognosis, some patients do not achieve remission despite a high serum concentration of canakinumab. Moreover, IBD may develop in CAPS following canakinumab treatment.

Source: Arthritis and Rheumatology - January 25, 2024 Category: Rheumatology Authors: Takayuki Miyamoto, Kazushi Izawa, Sho Masui, Atsue Yamazaki, Yuichi Yamasaki, Tadashi Matsubayashi, Mayuka Shiraki, Hidenori Ohnishi, Junko Yasumura, Kawabe Tomohiro, Takako Miyamae, Tomoyo Matsubara, Naoya Arakawa, Takashi Ishige, Takumi Ta Tags: Full Length Source Type: research